Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
2.490
+0.010 (0.40%)
At close: May 13, 2026, 4:00 PM EDT
2.450
-0.040 (-1.61%)
After-hours: May 13, 2026, 7:43 PM EDT
Company Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.
It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer’s disease.
The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Acumen Pharmaceuticals, Inc.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jul 1, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 61 |
| CEO | Daniel O'Connell |
Contact Details
Address: 1210-1220 Washington St., Suite 210 Newton, Massachusetts 02465 United States | |
| Phone | 617 344 4190 |
| Website | acumenpharm.com |
Stock Details
| Ticker Symbol | ABOS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1576885 |
| CUSIP Number | 00509G209 |
| ISIN Number | US00509G2093 |
| Employer ID | 36-4108129 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel J. O'Connell M.B.A. | Chief Executive Officer and Director |
| Dr. James Doherty Ph.D. | President and Chief Development Officer |
| Matt Zuga | Chief Financial Officer and Chief Business Officer |
| Dr. Grant A. Krafft Ph.D. | Co-Founder |
| Dr. Caleb E. Finch Ph.D. | Co-Founder |
| Dr. William L. Klein Ph.D. | Co-Founder |
| Russell Barton M.S. | Chief Operating Officer |
| Kelly Carranza | Senior Vice President of Finance and Accounting and Corporate Controller |
| Alex Braun M.B.A. | Vice President and Head of Investor Relations |
| Derek M. Meisner Esq., J.D. | Chief Legal Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| Apr 23, 2026 | ARS | Filing |
| Apr 23, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2026 | SCHEDULE 13G | Filing |
| Apr 1, 2026 | EFFECT | Notice of Effectiveness |
| Apr 1, 2026 | 424B3 | Prospectus |
| Mar 30, 2026 | UPLOAD | Filing |
| Mar 26, 2026 | S-3 | Registration statement under Securities Act of 1933 |